Is the investment opportunity of blood products sector coming?

Novel coronavirus pneumonia the enemy approached the walls of the city, and people are looking forward to the development of new drugs every hour and moment However, although vaccines and specific drugs have not yet been developed, there is another good news Previously, China Bio said that it had completed the collection of plasma from some rehabilitation patients and carried out the preparation of new coronavirus special immune plasma products and special immune globulin After strict blood biological safety test, virus inactivation, antiviral activity test and so on, we have successfully prepared the special plasma for clinical treatment China's biological announcement of novel coronavirus pneumonia was announced in the evening of February 13th The new high strength neutralizing antibody has been detected in plasma of the new crown pneumonia rehabilitative patient The experiment proved that the new crown virus can be effectively killed "We treated 11 critically ill patients with the special plasma of the rehabilitative patients The treatment effect is remarkable." What is the novel coronavirus treated with the specific plasma of the recovered person? Since novel coronavirus pneumonia is treated by the treatment of the clinical pathology, the body will produce specific antibodies against the new crown virus, which can kill and eliminate the virus Therefore, the use of this special plasma product for the treatment of new coronavirus infection can significantly reduce the mortality of critically ill patients The new crown plasma products are prepared from the plasma donated by the convalescent patients with high titer of new crown virus specific antibody, after virus inactivation, neutralizing antibody against new crown virus and detection of multiple pathogenic microorganisms And this kind of treatment, also known as "serum therapy", refers to a person suffering from a certain exogenous disease (such as virus), after treatment and recovery or obvious symptom relief, take the blood of the patient in recovery period (provided there is no risk of infectious disease), then separate the haemorrhagic serum, and then inject the serum into the patients with the same disease or individuals with close contact history Antibody against the virus has been produced in the serum of the convalescent, which can help the patient kill the virus and eventually make the patient recover; similarly, injecting the serum containing specific antibody into a special individual may also play a corresponding preventive role This serum therapy has been used since the outbreak of SARS in 2003 It has been carried out in Hong Kong and Singapore It has also proved that the use of serum from rehabilitation patients has a definite effect on the treatment of SARS However, serum therapy is always different from vaccines and specific drugs Its treatment requires a lot of serum, and if there are too many infected people, it will be very difficult to prepare special plasma products Therefore, China novel coronavirus pneumonia is also being recommended by Chinese residents 01 the opportunity brought by "new crown" to the blood products industry was stimulated by the news that "therapeutic new crown special exemption plasma products are put into clinical practice" The performance of the blood products sector in the A-share market is very strong On February 14, the A-share blood products plate opened high in the morning, the word board of Tiantan Biology (600161 SH), Shanghai Laishi (002252 SZ), Hualan Biology (002007 SZ), Boya Biology (300294 SZ) and so on also rose with it The new crown plasma project is undertaken by China Bio, and it has been put into clinical treatment of severe patients under the cooperation of China Bio Wuhan Institute of biological products, Wuhan blood products Co., Ltd of Sinopharm group, the first people's Hospital of Jiangxia District, Wuhan blood center, Wuhan Institute of viruses, Chinese Academy of Sciences and China food and drug testing and Research Institute Among them, Wuhan Institute of biological products of China biology holds 100% of the shares of China biology, while Wuhan blood products Co., Ltd of Sinopharm is mainly controlled by Tiantan biology, which holds 49.96% of the shares of China biology China's biological novel coronavirus has been launched in January 20th, and a special scientific research team has been set up to focus on new crown virus diagnostic reagents, new crown virus special plasma products, new crown virus specific immunoglobulin, new crown virus inactivated vaccine, recombinant vaccine of new crown virus, and new vaccine Research on coronavirus monoclonal antibody On January 26, as the first new coronavirus nucleic acid molecular detection kit developed by Shanghai Jienuo, a subsidiary of China biology, passed the emergency approval of the State Food and Drug Administration (only in 4 days), and obtained the registration certificate As of February 10, the test kit provided by Sinochem can be used for testing 1 million samples In addition, at the beginning of February, the first batch of interferon from Changchun company, a subsidiary of China biology, was sent to Wuhan, accumulatively supporting 12000 bottles in the front line of prevention and control In particular, products such as "jingc" produced by Tiantan biology have entered Wuhan huoshenshan hospital and leishenshan hospital It can be said that China Bio not only has a strong background, but also has a strong R & D strength Since the outbreak of the disease, Tiantan biology has received great attention from the capital market So, as the "blood product leader", the blood product plate where Tiantan biology is located, does it have investment value? Let's analyze it next 02 what is the current development of blood products industry? Blood products are mainly bioactive preparations made from healthy human plasma by biological process or separation and purification technology Blood products play an irreplaceable role in medical first aid and some specific diseases and treatment In short, blood products are derived from plasma, mainly including human albumin, immunoglobulin and coagulation factors Let's take a look at the types of blood products: among them, the proportion of albumin and intravenous immunoglobulin (human immunoglobulin for intravenous injection) batch issuance has increased rapidly in recent years As a whole, the consumption structure of blood products in China is mainly composed of human albumin and propafenone, accounting for nearly 80% of the total This is because albumin can correct acute blood volume reduction, prevent and control shock, and be used in cardiopulmonary bypass In particular, intravenous injection can prevent measles and infectious diseases If combined with antibiotics, it can improve the efficacy of some serious bacterial and viral infections Therefore, the novel coronavirus pneumonia needs a lot of static propane Data source: according to the data, there are 15 enterprises in China that produce Jing C with batch issuing records Among them, in 2019, the total number of static batch C issued reached 11.53 million bottles, a year-on-year increase of 9.60% From the perspective of the proportion of batch issuing enterprises, Tiantan biology accounts for the largest proportion, accounting for 26%; followed by Shanghai Laishi and Taibang biology, accounting for 13%; Hualan biology accounts for 12% At present, the annual pulp collection in the world is more than 50000 tons, of which 80% is in the United States; there are less than 20 blood products enterprises (excluding China), and the top four enterprises (shir / baxalta, CSL, octapharma, Grifols) account for about 80% of the global market share, with the annual pulp collection capacity of more than 5000 tons and the market value of more than 10 billion US dollars Due to the large population base, with the aging population and the increase of indications, the overall demand for blood products is still growing At present, the consumption structure of blood products in China is mainly composed of human albumin and propargyl chloride, accounting for nearly 80% of the total It can be seen that China's blood products market is in short supply From the plasma situation of six listed blood products companies in the A-share market, we can see that the plasma stations of Tiantan bio are the most, 55 in 2018, with plasma collection of 1568.07 tons, followed by Shanghai Laishi, with plasma stations of 41, with plasma collection of 1180 tons At the same time, the two companies also have the largest number of blood products, each with 12 varieties, while Hualan biological has 11 The number of pulp stations of these three listed companies accounts for 52.3% of the whole industry, and the pulp picking volume has exceeded 1100 tons For blood products enterprises, the core competitiveness is "taking the pulp as the king" In terms of operating revenue, take 2018 as an example, the sales revenue of blood products of Tiantan biology is 2.93 billion yuan, followed by Hualan biology, 2.41 billion yuan, and Shanghai Laishi, 1.8 billion yuan It can be seen that the three blood products enterprises have a great competitive advantage In particular, due to the huge demand for intravenous C in this pneumonia epidemic, Tiantan biology has benefited the most, and its performance flexibility is also the largest, followed by Hualan biology and Shanghai Laishi Conclusion we can see that with the continuous inventory clearing of blood products industry in recent years, the volume of plasma collection is also greatly increased, but the blood products market is still in short supply At the same time, the cost of pulp collection (such as pulp fee, wages of pulp collectors, etc.) is also increasing In terms of competing for the right of discourse and bargaining power for the downstream, major blood products enterprises pay more attention to research and development and academic promotion in order to face fierce market competition Therefore, we can see that the prosperity of blood products industry is very high In addition, due to the stimulation of external factors of pneumonia, the investment value of blood products companies will be very large in the future But no matter how good the industry is, there will always be some companies that are not worth investing in Therefore, for the investment of blood products companies, we should pay attention to the medium and long term, rather than short-term speculation Listen to the white statement: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.